Recent large-scale proteogenomic analyses found that mTOR and/or p-mTOR expression levels were significantly correlated with improved outcomes in RCC (Fan et al., 2020; Zhang et al., 2017), which was contradictory to the most widely accepted research and data. The gene discussed is MTOR; the disease is renal cell carcinoma.